Semaglutide (Ozempic, Wegovy) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management, formulated exclusively for subcutaneous injection into fatty tissue beneath the skin
Cholelithiasis in Patients Treated With Glucagon-Like Peptide-1 Receptor: An Updated Meta-Analysis of Randomized Controlled Trials
Plaintiffs contend that not all side effects, particularly severe ones like stomach paralysis, were adequately disclosed, posing significant health risks to users
Rybelsus (3mg to 14mg) is for type 2 diabetes, while the Wegovy pill (up to 25mg) is the version licensed for weight management
It is usually temporary and goes away after a few minutes, he says
The evidence for weight loss comes from the STEP 1 randomised double-blind trial, which compared a once weekly semaglutide injection with placebo[2]